Aptevo Therapeutics Inc. Share Price & Technical Analysis
APVO · $4.95 (-0.20%)
Healthcare / Biotechnology
$4.95
-0.20%
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune s…
Price chart
Seasonality
May has 1 positive and 3 negative years (last 5 years shown)
0% return in May, -25% avg return in past 3 year May month.
-49% return in 2026, -261% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -22% | 0% | -41% | 14% | 0% | – | – | – | – | – | – | – | -49% |
| 25 | -1% | -11% | -69% | -52% | -54% | -36% | -10% | -40% | -11% | 9% | -10% | -62% | -348% |
| 24 | -13% | 4% | -37% | -84% | -2% | -59% | 32% | -10% | -51% | 52% | 6% | -58% | -221% |
| 23 | -3% | -9% | -5% | -6% | -17% | -9% | -24% | -60% | -28% | -15% | -33% | -5% | -215% |
| 22 | -26% | -2% | 2% | -27% | 6% | -22% | 9% | -10% | -15% | 0% | 4% | -25% | -106% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Downtrend · Uptrend
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase 1b/2 clinical trial for the treatment of acute myelogenous leukemia. The company also develops ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for the treatment malignant pleural mesothelioma, non-small cell lung, gastric/gastro-esophageal, head and neck squamous cell carcinoma, pancreatic, renal, ovarian, prostate, breast, cervical, colorectal, endometrial, and bladder cancers; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate to treat multiple solid tumors; APVO442, a preclinical bispecific candidate based on the ADAPTIR-FLEX platform technology for the treatment of multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate to treat prostate cancer. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$5.75M
P/E ratio
—
52W high
$236.0
52W low
$3.80
Volume
26,618
Beta
1.65
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Aptevo Therapeutics Inc. share price today?
- Aptevo Therapeutics Inc. (APVO) last traded around $4.95 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does APVO have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for APVO. Download the app for real-time alerts.
- How can I analyze Aptevo Therapeutics Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.